Planegg/Martinsried (pta/16.03.2023/10:00 UTC+1)
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2023 being held on April 14-19, 2023.
The work to be presented shows that T cells carrying a NY-ESO-1-specific T cell receptor (TCR) combined with a chimeric PD1-41BB switch receptor, have significantly increased TCR-T cell proliferation, functionality and anti-tumor activity, compared to T cells expressing the TCR alone. A potential mechanism associated with this enhanced functionality is the greater release of multiple different effector cytokines.
The abstract for this research has been published online at https://www.abstractsonline.com/pp8/#!/10828/presentation/3341 and posters will be available online on April 18, 2023.
4057/9: T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors
Andrea Coluccio, Stefanie Tippmer, Petra Prinz, Maja Buerdek, Kathrin Mutze, Barbara Loesch, Kathrin Davari, Giulia Longinotti, Dolores J. Schendel.
Session details: Adoptive Cell and Natural Killer Cell Therapy
--- end of press release ---
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.
For more information, please visit www.medigene.com
About Medigene's TCR-T Therapy Platform
Medigene's immunotherapies help activate the patient's own defense mechanisms by harnessing T cells in the battle against cancer. Medigene's end-to-end platform combines multiple exclusive and proprietary technologies to create best-in-class TCR-T therapies. The platform includes multiple product enhancement technologies, (e.g. PD1-41BB Switch Receptor, Precision Pairing) and development optimization technologies (e.g. Allogeneic-HLA (Allo-HLA) TCR Priming) to aid the development of differentiated TCR-T therapies. Partnerships with multiple companies including BioNTech, 2SeventyBio, and Hongsheng Sciences, continue to validate the platform's assets & technologies.
About Medigene's MDG1015 Program
MDG1015 is a 3rd generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1, a well-recognized and validated cancer testis antigen which is expressed in multiple tumor types. MDG1015 contains our high-avidity, NY-ESO-1 TCR combined with our proprietary PD1-41BB co-stimulatory switch receptor that blocks the PD1/PD-L1 inhibitory axis while simultaneously activating the T cell through the well described -41BB pathway further enhancing the activity and persistence of the TCR-T in the hostile tumor microenvironment (TME). MDG1015 is currently undergoing IND/CTA enabling studies.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Phone: +49 89 2000 3333 01
Sandya von der Weid
Phone: +41 78 680 05 38
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (email@example.com). We will then delete your address from our distribution list.
Lochhamer Straße 11
|Contact Person:||Medigene PR/IR|
|Phone:||+49 89 2000 3333 01|
|Stock Exchange(s):||Regulated Market in Frankfurt, Free Market in Berlin, Free Market in Dusseldorf, Free Market in Hamburg, Free Market in Hannover, Free Market in Munich, Free Market in Stuttgart, Open Market in Tradegate|